Striatal and cerebellar vesicular acetylcholine transporter expression is disrupted in human DYT1 dystonia.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
12 04 2021
Historique:
received: 07 07 2020
revised: 03 10 2020
accepted: 23 10 2020
pubmed: 28 2 2021
medline: 14 8 2021
entrez: 27 2 2021
Statut: ppublish

Résumé

Early-onset torsion dystonia (TOR1A/DYT1) is a devastating hereditary motor disorder whose pathophysiology remains unclear. Studies in transgenic mice suggested abnormal cholinergic transmission in the putamen, but this has not yet been demonstrated in humans. The role of the cerebellum in the pathophysiology of the disease has also been highlighted but the involvement of the intrinsic cerebellar cholinergic system is unknown. In this study, cholinergic neurons were imaged using PET with 18F-fluoroethoxybenzovesamicol, a radioligand of the vesicular acetylcholine transporter (VAChT). Here, we found an age-related decrease in VAChT expression in the posterior putamen and caudate nucleus of DYT1 patients versus matched controls, with low expression in young but not in older patients. In the cerebellar vermis, VAChT expression was also significantly decreased in patients versus controls, but independently of age. Functional connectivity within the motor network studied in MRI and the interregional correlation of VAChT expression studied in PET were also altered in patients. These results show that the cholinergic system is disrupted in the brain of DYT1 patients and is modulated over time through plasticity or compensatory mechanisms.

Identifiants

pubmed: 33638639
pii: 6151672
doi: 10.1093/brain/awaa465
doi:

Substances chimiques

Molecular Chaperones 0
SLC18A3 protein, human 0
TOR1A protein, human 0
Vesicular Acetylcholine Transport Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

909-923

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Joachim Mazere (J)

Department of Nuclear Medicine, CHU de Bordeaux, France.
Institute of Cognitive and Integrative Neurosciences, CNRS UMR 5287, Bordeaux University, F33000, Bordeaux, France.

Bixente Dilharreguy (B)

Institute of Cognitive and Integrative Neurosciences, CNRS UMR 5287, Bordeaux University, F33000, Bordeaux, France.

Gwenaëlle Catheline (G)

Institute of Cognitive and Integrative Neurosciences, CNRS UMR 5287, Bordeaux University, F33000, Bordeaux, France.

Marie Vidailhet (M)

Institut du Cerveau et de la Moelle épinière (ICM) UMR 1127, hôpital de la Pitié-Salpétrière, Department of Neurology, AP-HP, Sorbonne Université, 75013, Paris, France.

Marc Deffains (M)

Institut des Maladies Neurodégénératives (IMN, CNRS U5393), Université de Bordeaux, 33076, Bordeaux, France.

Delphine Vimont (D)

Department of Nuclear Medicine, CHU de Bordeaux, France.
Institute of Cognitive and Integrative Neurosciences, CNRS UMR 5287, Bordeaux University, F33000, Bordeaux, France.

Bastien Ribot (B)

Institut des Maladies Neurodégénératives (IMN, CNRS U5393), Université de Bordeaux, 33076, Bordeaux, France.

Elodie Barse (E)

Institute of Cognitive and Integrative Neurosciences, CNRS UMR 5287, Bordeaux University, F33000, Bordeaux, France.

Laura Cif (L)

Department of Neurosurgery, CHU de Montpellier, 34000, France.

Bernard Mazoyer (B)

Institut des Maladies Neurodégénératives (IMN, CNRS U5393), Université de Bordeaux, 33076, Bordeaux, France.

Nicolas Langbour (N)

Centre de Recherche en Psychiatrie, CH de la Milétrie, 86000, Poitiers, France.

Antonio Pisani (A)

Department of Brain and Behavioural Sciences, University of Pavia, Italy.
IRCCS Mondino Foundation, Pavia, Italy.

Michèle Allard (M)

Department of Nuclear Medicine, CHU de Bordeaux, France.
Institute of Cognitive and Integrative Neurosciences, CNRS UMR 5287, Bordeaux University, F33000, Bordeaux, France.

Frédéric Lamare (F)

Department of Nuclear Medicine, CHU de Bordeaux, France.
Institute of Cognitive and Integrative Neurosciences, CNRS UMR 5287, Bordeaux University, F33000, Bordeaux, France.

Dominique Guehl (D)

Institut des Maladies Neurodégénératives (IMN, CNRS U5393), Université de Bordeaux, 33076, Bordeaux, France.
Service de Neurophysiologie Clinique, Pôle des Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France.

Philippe Fernandez (P)

Department of Nuclear Medicine, CHU de Bordeaux, France.
Institute of Cognitive and Integrative Neurosciences, CNRS UMR 5287, Bordeaux University, F33000, Bordeaux, France.

Pierre Burbaud (P)

Institut des Maladies Neurodégénératives (IMN, CNRS U5393), Université de Bordeaux, 33076, Bordeaux, France.
Service de Neurophysiologie Clinique, Pôle des Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH